ERBB2 and breast carcinoma: Similarly, the PATRICIA study, a single-arm phase II trial, demonstrated an objective response rate (ORR) of 11% with pertuzumab in combination with high-dose trastuzumab in patients with HER2+ breast cancer and brain metastases.